A New Rapid-Acting Antidepressant

John H. Krystal, Dennis S. Charney, Ronald S. Duman

Research output: Contribution to journalComment/debate

21 Scopus citations


The discovery of the strikingly rapid and robust antidepressant effects of r/s-ketamine for the treatment of antidepressant-resistant symptoms of depression has led to new insights into the biology of antidepressants and the FDA approval of its s-isomer, Esketamine (Spravato), the first mechanistically new treatment for depression in over 60 years. To view this Bench to Bedside, open or download the PDF.

Original languageEnglish
Pages (from-to)7
Number of pages1
Issue number1
StatePublished - 2 Apr 2020
Externally publishedYes


Dive into the research topics of 'A New Rapid-Acting Antidepressant'. Together they form a unique fingerprint.

Cite this